A.D. Beadell Investment Counsel’s AstraZeneca AZN Stock Holding History

A.D. Beadell Investment Counsel’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.13M	Sell	6,968 -7	-0.1%	-$1.17K	0.74%	44
2026 Q2	$1.32M	Hold	6,975	–	–	0.85%	41
2026 Q1	$1.38M	Sell	6,975 -5	-0.1%	-$964	0.88%	41
2025 Q4	$1.28M	Hold	6,980	–	–	0.83%	42
2025 Q3	$1.07M	Hold	6,980	–	–	0.73%	49
2025 Q2	$975K	Hold	6,980	–	–	0.74%	48
2025 Q1	$1.03M	Buy	6,980 +287	+4%	+$41.5K	0.85%	43
2024 Q4	$876K	Buy	+6,693	New	+$937K	0.71%	50

Other funds holding AZN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Border to Coast Pensions Partnership Leeds, United Kingdom $7.27B AUM 24.98% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

ZWJ Investment Counsel Atlanta, Georgia $3.24B AUM 31.6% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Oslo Pensjonsforsikring Oslo $863M AUM 18.29% 1-Year Est. Return

PAS

Professional Advisory Services Vero Beach, Florida $837M AUM 20.44% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return

LPPL

Loftus Peak Pty Ltd Sydney, Australia $781M AUM

A.D. Beadell Investment Counsel's AZN Position: Q3 2026 in Review

A.D. Beadell Investment Counsel reduced its AstraZeneca (AZN) stake by 0.1% in Q3 2026, selling an estimated $1.17K and leaving 6,968 shares worth $1.13M. The position accounts for 0.74% of the portfolio, ranked #44.

A.D. Beadell Investment Counsel first reported a position in AZN in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.38M in Q1 2026. 174 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

A.D. Beadell Investment Counsel held 6,968 shares of AstraZeneca worth $1.13M as of Q3 2026.
A.D. Beadell Investment Counsel sold 7 AstraZeneca shares in Q3 2026, an estimated $1.17K.
AstraZeneca made up 0.74% of A.D. Beadell Investment Counsel's portfolio in Q3 2026, its #44 holding.
A.D. Beadell Investment Counsel first reported a position in AstraZeneca in Q4 2024 and has held it in 8 quarters since.
A.D. Beadell Investment Counsel's AstraZeneca position peaked at $1.38M in Q1 2026.
174 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on A.D. Beadell Investment Counsel's 13F filing for Q3 2026, filed 14 Oct 2026.